ACCU-BREAK Pharmaceuticals, Inc. Announces Appointment of Lawrence Rosenthal, Former President of Andrx Pharmaceuticals, Inc.

PLANTATION, Fla. -- ACCU-BREAK Pharmaceuticals, Inc. ("ABP" or the "Company"), announced today that Lawrence Rosenthal has been named Vice President of the Company and President of its wholly-owned subsidiary, ACCU-BREAK Generics, Inc. Previously, Mr. Rosenthal served as President of Andrx Pharmaceuticals, Inc., a subsidiary of Andrx Corporation, which was recently acquired by Watson Pharmaceuticals, Inc. (NYSE:WPI). Mr. Rosenthal has also been Vice President, Sales and Marketing of Teva Pharmaceuticals, Inc. USA (NASDAQ:TEVA). He is a long standing member of the Board of Directors of the Generic Pharmaceutical Association.

Elliot F. Hahn, Ph.D., President of ABP, stated, "I look forward to working with Larry again and welcome him to our team. The breadth of his business experience will allow him to make a major contribution to the development and marketing of bioequivalent products utilizing the ACCU-BREAK[TM] technologies, as well as allowing him to play an important role in our technology out-licensing efforts."

ABP has filed approximately twenty (20) U.S. patent applications to protect the ACCU-BREAK technologies. ACCU-BREAK tablets are designed to be easily breakable by patients into precise half or quarter doses. This may enhance the ability of physicians to adjust doses whenever needed and also provide patients the potential to save money on their generic drugs.

Mr. Rosenthal commented, "I am excited about the benefits that ACCU-BREAK-enabled tablets may offer to physicians, patients and the pharmaceutical industry. I look forward to joining the Company's efforts to market a family of ACCU-BREAK generic products as well as its efforts to license these technologies to other pharmaceutical companies."

ACCU-BREAK Pharmaceuticals, Inc. is a privately-held, technology-based pharmaceutical company. It is engaged in bioequivalent ACCU-BREAK product development through a joint venture with Strides Arcolab Ltd. of Bangalore, India. The Company intends to make its technologies available for licensing, primarily to enhance the sales and life-cycle management potential of brand products. ABP also has a brand product development program, for which several patents are pending.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they use words such as "may," "will," "to," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. All forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement related to product liability, patent protection, governmental investigations, and other legal proceedings; ABP's ability to acquire and protect patents and other intellectual property both domestically and internationally; the ability to license our technology, the absence of certainty regarding the receipt of required regulatory approvals or the timing or terms of such approvals; and any changes in business, political, and economic conditions. Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. ABP disclaims any responsibility to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.